Probiotics, symptoms, and gut microbiota: what are the relations? A randomized controlled trial in subjects with irritable bowel syndrome

Per G Farup, Morten Jacobsen, Solveig C Ligaarden, Knut Rudi, Per G Farup, Morten Jacobsen, Solveig C Ligaarden, Knut Rudi

Abstract

Introduction. Knowledge of the mechanism of action of probiotics in subjects with irritable bowel syndrome (IBS) is imperfect. Objective. This trial aimed at discriminating between a direct effect on the gut wall and an indirect effect caused by modulation of the fecal microbiota. Design. Randomized, double-blind, crossover trial. Material and Methods. Patients with IBS were given one capsule of 10(10) CFU L. plantarum MF 1298 or placebo once daily. Symptoms were registered (score 0-15) and feces collected at the end of each period. The gut microbiota was analyzed with 16S rRNA gene analyses and results reported as proportions of Bacteroides, Faecalibacterium, and Lachnospiraceae and Simpson's D diversity score. Results. Sixteen participants (11 women) with a mean age of 50 years (SD 11) were available for the analyses. Intake of L. plantarum MF 1298 was associated with a significant aggravation of symptoms, but neither intake of L. plantarum MF 1298 nor symptoms were associated with the composition of the fecal microbiota (P values >0.10). Conclusions. The trial indicates that the symptomatic aggravation related to intake of L. plantarum MF 1298 was a direct effect of the microbe on the gut wall and not caused by changes in the fecal microbiota.

Figures

Figure 1
Figure 1
A schematic presentation of all results in the trial showing the associations between treatment with probiotics (Lp MF 1298), the fecal microbiota (composition and diversity), and symptoms.

References

    1. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133(1):24–33.
    1. Rajilić-Stojanović M, Biagi E, Heilig HGHJ, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141(5):1792–1801.
    1. Parkes GC, Rayment NB, Hudspith BN, et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterology and Motility. 2012;24(1):31–39.
    1. Codling C, O’Mahony L, Shanahan F, Quigley EMM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Digestive Diseases and Sciences. 2010;55(2):392–397.
    1. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Alimentary Pharmacology and Therapeutics. 2005;22(5):387–394.
    1. Ligaarden SC, Axelsson L, Naterstad K, Lydersen S, Farup PG. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterology. 2010;10, article 16
    1. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325–332.
    1. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterology. 2009;9, article 15
    1. Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: probiotics for the treatment of irritable bowel syndrome—focus on lactic acid bacteria. Alimentary Pharmacology and Therapeutics. 2012;35(4):403–413.
    1. Lee BJ, Bak Y-T. Irritable bowel syndrome, gut microbiota and probiotics. Journal of Neurogastroenterology and Motility. 2011;17(3):252–266.
    1. Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. American Journal of Gastroenterology. 2008;103(6):1557–1567.
    1. Spiller R. Review article: probiotics and prebiotics in irritable bowel syndrome. Alimentary Pharmacology and Therapeutics. 2008;28(4):385–396.
    1. Reiff C, Kelly D. Inflammatory bowel disease, gut bacteria and probiotic therapy. International Journal of Medical Microbiology. 2010;300(1):25–33.
    1. Sun J, Yoon SS. Probiotics, nuclear receptor signaling, and anti-inflammatory pathways. Gastroenterology Research and Practice. 2011;2011:16 pages.971938
    1. Skånseng B, Kaldhusdal M, Rudi K. Comparison of chicken gut colonisation by the pathogens Campylobacter jejuni and Clostridium perfringens by real-time quantitative PCR. Molecular and Cellular Probes. 2006;20(5):269–279.
    1. Trosvik P, Skånseng B, Jakobsen KS, Stenseth NC, Næs T, Rudi K. Multivariate analysis of complex DNA sequence electropherograms for high-throughput quantitative analysis of mixed microbial populations. Applied and Environmental Microbiology. 2007;73(15):4975–4983.
    1. Zimonja M, Rudi K, Trosvik P, Næs T. Multivariate curve resolution of mixed bacterial DNA sequence spectra: identification and quantification of bacteria in undefined mixture samples. Journal of Chemometrics. 2008;22(5):309–322.
    1. Chu ZX, Chen HQ, Ma YL, et al. Lactobacillus plantarum prevents the upregulation of adhesion molecule expression in an experimental colitis model. Digestive Diseases and Sciences. 2010;55(9):2505–2513.
    1. Chen HQ, Yang J, Zhang M, et al. Lactobacillus plantarum ameliorates colonic epithelial barrier dysfunction by modulating the apical junctional complex and PepT1 in IL-10 knockout mice. American Journal of Physiology. 2010;299(6):G1287–G1297.
    1. Klingberg TD, Pedersen MH, Cencic A, Budde BB. Application of measurements of transepithelial electrical resistance of intestinal epithelial cell monolayers to evaluate probiotic activity. Applied and Environmental Microbiology. 2005;71(11):7528–7530.
    1. Klingberg TD, Axelsson L, Naterstad K, Elsser D, Budde BB. Identification of potential probiotic starter cultures for Scandinavian-type fermented sausages. International Journal of Food Microbiology. 2005;105(3):419–431.
    1. Zoetendal EG, Von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans ADL, De Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Applied and Environmental Microbiology. 2002;68(7):3401–3407.
    1. Jeffery IB, O'Toole PW, Öhman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997–1006.
    1. Dear KLE, Elia M, Hunter JO. Do interventions which reduce colonic bacterial fermentation improve symptoms of irritable bowel syndrome? Digestive Diseases and Sciences. 2005;50(4):758–766.
    1. Lyra A, Krogius-Kurikka L, Nikkilä J, et al. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterology. 2010;10, article 110
    1. Kajander K, Myllyluoma E, Rajilić-Stojanović M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Alimentary Pharmacology and Therapeutics. 2008;27(1):48–57.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever